home / stock / bctxf / bctxf news

BCTXF News and Press, BriaCell Therapeutics From 11/12/19

Stock Information
Company Name: BriaCell Therapeutics
Stock Symbol: BCTXF
Market: OTC
Website: briacell.com
Menu
BCTXF BCTXF Quote BCTXF Short BCTXF News BCTXF Articles BCTXF Message Board
Get BCTXF Alerts

News, Short Squeeze, Breakout and More Instantly...
BCTXF - BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in combination with pembrolizumab (KEYTRUDA ® ; by Merck & Co., Inc.); Bria-IMT™...
BCTXF - BriaCell Announces Voting Results of the Special Meeting of Shareholders

BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announce...

BCTXF - BriaCell Announces Closing of Non-Brokered Private Placement of $568,444

BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 15, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces tha...

BCTXF - BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for adva...
BCTXF - BriaCell CEO: Incyte Collaboration Enabling New Clinical Trials for Breast Cancer Treatments

With 12 percent of women in the United States expected to develop a form of breast cancer at some point in their life, there is an urgent need for solutions to combat one of the most deadly forms of cancer in the world today. In pursuit of this goal, biotechnology company BriaCell Therapeut...

BCTXF - BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT(TM) in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing ...

BCTXF - BriaCell Therapeutics Corp. to Clarify Record Date

BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advan...
BCTXF - Note from Chairman of BriaCell Therapeutics - October is Breast Cancer Awareness Month

BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.  Octob...

BCTXF - BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special 'Targeted Immunotherapy' Issue in Prestigious Journals

BERKELEY, Calif., and VANCOUVER, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announ...

BCTXF - BriaCell announces private placement of up to $0.6M

BriaCell Therapeutics ( OTCQB:BCTXF -19.9% ) announce a non-brokered private placement of up to ~8.57M common shares for gross proceeds of up to ~ C$0.6M at a price of C$0.07/share. More news on: BriaCell Therapeutics Corp., Read more ...

Previous 10 Next 10